Accounts Receivables - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.1 PLN -1.64% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ryvu Therapeutics SA
Accounts Receivables Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Accounts Receivables
zł11.5m
CAGR 3-Years
97%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Accounts Receivables
zł665k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Medicofarma Biotech SA
WSE:MDB
Accounts Receivables
zł422.8k
CAGR 3-Years
248%
CAGR 5-Years
43%
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Accounts Receivables
zł67.5m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Accounts Receivables?
Accounts Receivables
11.5m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Accounts Receivables amounts to 11.5m PLN.

What is Ryvu Therapeutics SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
97%

Over the last year, the Accounts Receivables growth was 7%. The average annual Accounts Receivables growth rates for Ryvu Therapeutics SA have been 97% over the past three years .

Back to Top